Paricalcitol ( DrugBank: Paricalcitol )

5 diseases

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02090608 (ClinicalTrials.gov)	March 2012	14/3/2014	Paricalcitol in Fabry Disease		Fabry Disease;Proteinuria	Drug: Paricalcitol	Federico II University	NULL	Completed	18 Years	75 Years	Both	14	N/A	Italy

臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00599963 (ClinicalTrials.gov)	January 2008	2/1/2008	Paricalcitol for the Treatment of Immunoglobulin A Nephropathy	Paricalcitol for the Treatment of Immunoglobulin A Nephropathy - A Randomized Cross-Over Study	IgA Nephropathy	Drug: paricalcitol	Chinese University of Hong Kong	NULL	Withdrawn	18 Years	65 Years	Both	0	Phase 3	Hong Kong;China

臨床試験数 : 30 / 薬物数 : 36 - (DrugBank : 15) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 46

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02378805 (ClinicalTrials.gov)	July 1995	26/2/2015	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome	European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies	Familial Benign Hematuria;Alport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease;Thin Basement Membrane Disease	Drug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: Paricalcitol;Drug: SGLT2 inhibitor	University Hospital Goettingen	Society for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive Medicine	Recruiting	N/A	N/A	All	500		Germany

臨床試験数 : 28 / 薬物数 : 20 - (DrugBank : 9) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 16

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00417612 (ClinicalTrials.gov)	January 2007	28/12/2006	Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets	The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH)	Hypophosphatemia, Familial;Hyperparathyroidism	Drug: Paricalcitol;Other: Placebo	Yale University	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Completed	9 Years	N/A	All	33	Phase 3	United States

臨床試験数 : 95 / 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05664880 (ClinicalTrials.gov)	January 2023	7/12/2022	A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis	A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis	Chronic Pancreatitis	Drug: Paricalcitol;Drug: Placebo	Cedars-Sinai Medical Center	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Not yet recruiting	18 Years	75 Years	All	24	Early Phase 1	United States